Galleria mellonella as an Antimicrobial Screening Model
Journal of Visualized Experiments · 2024-10-11 · (212)
DOI: 10.3791/67210 ↗At a glance
Video/Audio in Journal of Visualized Experiments, published online on 2024-10-11. Written by Thomas E Barton and 4 co-authors. Institution: Division of Molecular Microbiology, School of Life Sciences, University of Dundee; 2598559@dundee.ac.uk. Major MEDLINE topics: Moths, Larva, Pseudomonas aeruginosa, Disease Models, Animal. Cited 10 times so far (Crossref); 34 references.
Abstract (original language)
To combat the rising global issue of antibiotic resistance, the accelerated development of novel antibiotics is essential. Current preclinical antimicrobial development yields a significant number of leads that prove unsuitable either prior to or during clinical trials. To increase the efficiency of preclinical development, relevant, standardized, accessible, and cost-effective models must be developed. Galleria mellonella (greater wax moth) larvae are widely used as an infection model to assess microbial virulence, conduct drug toxicity testing, and serve as a preliminary means of evaluating the in vivo efficacy of novel antimicrobial compounds. These infection models have greater biological relevance than many in vitro screens of comparable throughput and decrease reliance on mammalian models when used as a pre-screen for antimicrobial testing. This protocol describes a standardized methodology for the optimization of G. mellonella infection models, which can be applied to bacterial species and antimicrobial therapeutics of choice. Using the WHO priority pathogen Pseudomonas aeruginosa as an exemplar, we outline steps that can be undertaken to develop a reproducible model of infection and therapeutic testing. This includes recommendations on experimental setup, sample preparation, and infection and treatment protocols. Integration of this model within preclinical antimicrobial development pipelines would decrease reliance on mammalian models, reduce the number of ineffective compounds reaching clinical trials, and ultimately increase the efficiency of preclinical antimicrobial development.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Division of Molecular Microbiology, School of Life Sciences, University of Dundee; 2598559@dundee.ac.uk.
- Department of Clinical Infection, Microbiology and Immunology, University of Liverpool.
- Division of Molecular Microbiology, School of Life Sciences, University of Dundee.
Cite
APA
Barton, T. E., Duignan, L., Kadioglu, A., Fothergill, J. L., & Neill, D. R. (2024). Galleria mellonella as an Antimicrobial Screening Model. Journal of Visualized Experiments. https://doi.org/10.3791/67210
Vancouver
Barton TE, Duignan L, Kadioglu A, Fothergill JL, Neill DR. Galleria mellonella as an Antimicrobial Screening Model. Journal of Visualized Experiments. 2024. doi:10.3791/67210
BibTeX
@article{Barton2024,
author = {Barton, Thomas E and Duignan, Liberty and Kadioglu, Aras and Fothergill, Joanne L and Neill, Daniel R},
title = {Galleria mellonella as an Antimicrobial Screening Model},
journal = {Journal of Visualized Experiments},
year = {2024},
number = {212},
doi = {10.3791/67210}
}
EUVIMED